Talakad G Lohith1, Idriss Bennacef1, Rik Vandenberghe2, Mathieu Vandenbulcke2, Cristian A Salinas1, Ruben Declercq3, Tom Reynders3, N Florestina Telan-Choing4, Kerry Riffel1, Sofie Celen5, Kim Serdons6, Guy Bormans5, Kuenhi Tsai7, Abbas Walji8, Eric D Hostetler1, Jeffrey L Evelhoch1, Koen Van Laere6, Mark Forman9, Aubrey Stoch9, Cyrille Sur1, Arie Struyk10. 1. Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania. 2. Neurology Department, University Hospitals Leuven, Leuven, Belgium; Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium; Alzheimer Research Centre, KU Leuven, Leuven Institute for Neuroscience and Disease, Leuven, Belgium. 3. Translational Pharmacology Europe, Merck Sharp & Dohme Corp., Brussels, Belgium. 4. Translational Pharmacology Clinical Operations, Merck & Co., Inc., North Wales, Pennsylvania. 5. Radiopharmaceutical Research, KU Leuven, Leuven, Belgium. 6. Division of Nuclear Medicine, University Hospitals Leuven and UZ Leuven, Leuven, Belgium. 7. Early Clinical Statistics, Merck & Co., Inc., West Point, Pennsylvania. 8. Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania; and. 9. Translational Pharmacology, Merck & Co., Inc., North Wales, Pennsylvania. 10. Translational Pharmacology, Merck & Co., Inc., North Wales, Pennsylvania arie_struyk@merck.com.
Abstract
18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary tangles (NFTs). Plasma kinetics, brain uptake, and preliminary quantitative analysis of 18F-MK-6240 in healthy elderly (HE) subjects, subjects with clinically probable Alzheimer disease (AD), and subjects with amnestic mild cognitive impairment were characterized in a study that is, to our knowledge, the first to be performed on humans. Methods: Dynamic PET scans of up to 150 min were performed on 4 cognitively normal HE subjects, 4 AD subjects, and 2 amnestic mild cognitive impairment subjects after a bolus injection of 152-169 MBq of 18F-MK-6240 to evaluate tracer kinetics and distribution in brain. Regional SUV ratio (SUVR) and distribution volume ratio were determined using the cerebellar cortex as a reference region. Total distribution volume was assessed by compartmental modeling using radiometabolite-corrected input function in a subgroup of 6 subjects. Results: 18F-MK-6240 had rapid brain uptake with a peak SUV of 3-5, followed by a uniformly quick washout from all brain regions in HE subjects; slower clearance was observed in regions commonly associated with NFT deposition in AD subjects. In AD subjects, SUVR between 60 and 90 min after injection was high (approximately 2-4) in regions associated with NFT deposition, whereas in HE subjects, SUVR was approximately 1 across all brain regions, suggesting high tracer selectivity for binding NFTs in vivo. 18F-MK-6240 total distribution volume was approximately 2- to 3-fold higher in neocortical and medial temporal brain regions of AD subjects than in HE subjects and stabilized by 60 min in both groups. Distribution volume ratio estimated by the Logan reference tissue model or compartmental modeling correlated well (R 2 > 0.9) to SUVR from 60 to 90 min for AD subjects. Conclusion: 18F-MK-6240 exhibited favorable kinetics and high binding levels to brain regions with a plausible pattern for NFT deposition in AD subjects. In comparison, negligible tracer binding was observed in HE subjects. This pilot study suggests that simplified ratio methods such as SUVR can be used to quantify NFT binding. These results support further clinical development of 18F-MK-6240 for potential application in longitudinal studies.
18F-MK-6240 (18F-labeled 6-(fluoro)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine) is a highly selective, subnanomolar-affinity PET tracer for imaging neurofibrillary tangles (NFTs). Plasma kinetics, brain uptake, and preliminary quantitative analysis of 18F-MK-6240 in healthy elderly (HE) subjects, subjects with clinically probable Alzheimer disease (AD), and subjects with amnestic mild cognitive impairment were characterized in a study that is, to our knowledge, the first to be performed on humans. Methods: Dynamic PET scans of up to 150 min were performed on 4 cognitively normal HE subjects, 4 AD subjects, and 2 amnestic mild cognitive impairment subjects after a bolus injection of 152-169 MBq of 18F-MK-6240 to evaluate tracer kinetics and distribution in brain. Regional SUV ratio (SUVR) and distribution volume ratio were determined using the cerebellar cortex as a reference region. Total distribution volume was assessed by compartmental modeling using radiometabolite-corrected input function in a subgroup of 6 subjects. Results:18F-MK-6240 had rapid brain uptake with a peak SUV of 3-5, followed by a uniformly quick washout from all brain regions in HE subjects; slower clearance was observed in regions commonly associated with NFT deposition in AD subjects. In AD subjects, SUVR between 60 and 90 min after injection was high (approximately 2-4) in regions associated with NFT deposition, whereas in HE subjects, SUVR was approximately 1 across all brain regions, suggesting high tracer selectivity for binding NFTs in vivo. 18F-MK-6240 total distribution volume was approximately 2- to 3-fold higher in neocortical and medial temporal brain regions of AD subjects than in HE subjects and stabilized by 60 min in both groups. Distribution volume ratio estimated by the Logan reference tissue model or compartmental modeling correlated well (R 2 > 0.9) to SUVR from 60 to 90 min for AD subjects. Conclusion:18F-MK-6240 exhibited favorable kinetics and high binding levels to brain regions with a plausible pattern for NFT deposition in AD subjects. In comparison, negligible tracer binding was observed in HE subjects. This pilot study suggests that simplified ratio methods such as SUVR can be used to quantify NFT binding. These results support further clinical development of 18F-MK-6240 for potential application in longitudinal studies.
Authors: Michel Koole; Talakad G Lohith; John L Valentine; Idriss Bennacef; Ruben Declercq; Tom Reynders; Kerry Riffel; Sofie Celen; Kim Serdons; Guy Bormans; Sandrine Ferry-Martin; Philippe Laroque; Abbas Walji; Eric D Hostetler; Richard J Briscoe; Jan de Hoon; Cyrille Sur; Koen Van Laere; Arie Struyk Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488
Authors: Nicolas J Guehl; Dustin W Wooten; Georges El Fakhri; Marc D Normandin Journal: Eur J Nucl Med Mol Imaging Date: 2020-06-18 Impact factor: 9.236
Authors: Nicolas J Guehl; Dustin W Wooten; Daniel L Yokell; Sung-Hyun Moon; Maeva Dhaynaut; Samantha Katz; Kirsten A Moody; Codi Gharagouzloo; Aurélie Kas; Keith A Johnson; Georges El Fakhri; Marc D Normandin Journal: Eur J Nucl Med Mol Imaging Date: 2019-07-22 Impact factor: 9.236
Authors: Greet Vanderlinden; Jenny Ceccarini; Thomas Vande Casteele; Laura Michiels; Robin Lemmens; Eric Triau; Kim Serdons; Jos Tournoy; Michel Koole; Mathieu Vandenbulcke; Koen Van Laere Journal: Mol Psychiatry Date: 2022-07-06 Impact factor: 15.992
Authors: David N Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Viktoriya Bourakova; Adam L Boxer; Lauren Edwards; Rana Eser; Maria-Luisa Gorno-Tempini; William J Jagust; Mustafa Janabi; Joel H Kramer; Orit H Lesman-Segev; Taylor Mellinger; Bruce L Miller; Julie Pham; Howard J Rosen; Salvatore Spina; William W Seeley; Amelia Strom; Lea T Grinberg; Gil D Rabinovici Journal: Brain Date: 2020-12-05 Impact factor: 13.501